The reason for this significant decrease is the company's announcement that it is seeking shareholder approval to cancel its listing on the London Stock Exchange (LON:LSEG)'s junior AIM.

Synairgen, a Southampton-based respiratory company developing antiviral protein interferon beta, has revealed plans to cancel its AIM listing.

Hornby is seeking shareholder approval to cancel trading of its shares on London's junior AIM, saying it believes re-registering as a private company would better allow it to continue its ...